[Natulan (experimental and clinical data on its antitumor effect)].
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D001984:Bronchial Neoplasms / Q000188:drug therapy; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D011087:Polycythemia Vera / Q000188:drug therapy; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D001565:Benzoates; D011838:Radiation-Sensitizing Agents; D011344:Procarbazine
Natulan (éksperimental'nye i klinicheskie materialy o protivoopukholevom éffekte.